Increased treatment adherence in patients with chronic obstructive pulmonary disease when using a fixed triple combination

Introduction. Poor medication adherence significantly increases the likelihood of complications, which leads to a decrease in quality of life (QoL) in patients and an increase in treatment costs.

Goal. To study the adherence and effectiveness of treatment in COPD patients (group D) using a fixed triple combination of vilanterol/umeclidinium bromide/fluticasone furoate (FF/UMEC/VI).

Material and methods. The study included 26 male patients with severe COPD with frequent exacerbations (group D). All patients were recommended therapy with a fixed triple combination of vilanterol/umeclidinium bromide/fluticasone furoate (FF/UMEC/VI). Patients were monitored for 12 months, and the following endpoints were recorded: hospitalization due to exacerbation of COPD, progression of COPD (decrease in FEV1), and death of the patient. In addition, the dynamics of treatment adherence, the number of SAT test scores, and the level of depression on the Beck scale were evaluated.

Results. After 6 months of taking a fixed triple combination of FF/UMEC/VI, there was an improvement in treatment adherence in the form of a 15.3% decrease in the proportion of non-committed patients with COPD and an increase in the proportion of patients committed to therapy by 7.7%; the average frequency of exacerbations significantly decreased, this dynamics remained by the 12th month of follow-up. After 12 months, patients with COPD showed a statistically significant decrease in the proportion of patients who were not committed to treatment and a statistically significant increase in the proportion of patients who were committed to treatment for COPD; there was a statistically significant decrease in the frequency of severe depression in COPD patients; there was a statistically significant decrease in the proportion of patients with severe and moderate COPD influence on the quality of life.

Conclusion. The results of our study confirmed the view that adherence plays a significant role in the effectiveness of treatment of COPD patients, and the use of a fixed triple combination of FF/UMEC/VI helps to increase it.

1. Menditto E., Cahir C., Malo S., Aguilar-Palacio I., Almada M., Costa E. et al. Persistence as a Robust Indicator of Medication Adherence-Related Quality and Performance. Int J Environ Res Public Health. 2021;18(9):4872. https://doi.org/10.3390/ijerph18094872.

2. Stirratt M.J., Curtis J.R., Danila M.I., Hansen R., Miller M.J., Gakumo C.A. Advancing the Science and Practice of Medication Adherence. J Gen Intern Med. 2018;33(2):216–222. https://doi.org/10.1007/s11606-017-4198-4.

3. Vizel A.A., Vizel I.Yu., Salakhova I.N., Vafina A.R. Adherence in Bronchial Asthma and Chronic Obstructive Pulmonary Disease: From a Problem to a Solution. Farmateka. 2019;26(5):122–126. (In Russ.) https://doi.org/10.18565/pharmateca.2019.5.122-126.

4. Bogart M., Stanford R.H., Laliberté F., Germain G., Wu J.W., Duh M.S. Medication Adherence and Persistence in Chronic Obstructive Pulmonary Disease Patients Receiving Triple Therapy in a USA Commercially Insured Population. Int J Chron Obstruct Pulmon Dis. 2019;14:343–352. https://doi.org/10.2147/COPD.S184653.

5. Vogelmeier C.F., Román-Rodríguez M., Singh D., Han M.K., RodríguezRoisin R., Ferguson G.T. Goals of COPD Treatment: Focus on Symptoms and Exacerbations. Respir Med. 2020;166:105938. https://doi.org/10.1016/j.rmed.2020.105938.

6. Avdeev S.N., Aisanov Z.R., Belevsky A.S., Bi K.M., Vizel A.A., Zyryanov S.K. et al. The Concept of Chronic Obstructive Pulmonary Disease Clinical Control as a Decision-Making Tool in Real Clinical Practice for Optimizing of Basic Pharmacotherapy. Terapevticheskii arkhiv = Therapeutic Archive. 2020;92(1):89–95. (In Russ.) https://doi.org/10.26442/00403660.2020.01.000489.

7. Vizel A.A., Belevskiy A.S., Vizel I.Yu., Salakhova I.N. Triple Inhalation Therapy: From Free Combination to Fixed Combination. Prakticheskaya pulmonologiya = Practical Pulmonology. 2020;(2):42–49. (In Russ.) Available at: http://www.atmosphere-ph.ru/modules/Magazines/articles//pulmo/pp_2_2020_42.pdf.

8. Morisky D.E., Green L.W., Levine D.M. Concurrent and Predictive Validity of a Self-Reported Measure of Medication Adherence. Med Care. 1986;24(1):67–74. https://doi.org/10.1097/00005650-198601000-00007.

9. ElSaygh J., Zaher A., Nathani P., Omballi M. A Review of Clinical Trials That Contributed to Chronic Obstructive Pulmonary Disease Treatment Protocols. Cureus. 2021;13(4):e14618. https://doi.org/10.7759/cureus.14618.

10. Siler T.M., Kerwin E., Sousa A.R., Donald A., Ali R., Church A. Efficacy and Safety of Umeclidinium Added to Fluticasone Furoate/Vilanterol in Chronic Obstructive Pulmonary Disease: Results of Two Randomized Studies. Respir Med. 2015;109(9):1155–1163. https://doi.org/10.1016/j.rmed.2015.06.006.

11. Halpin D.M.G., Dransfield M.T., Han M.K., Jones C.E., Kilbride S., Lange P. et al. The Effect of Exacerbation History on Outcomes in the IMPACT Trial. Eur Respir J. 2020;55:1901921. https://doi.org/10.1183/13993003.01921-2019.

12. Lipson D.A., Crim C., Criner G.J., Day N.C., Dransfield M.T., Halpin D.M.G. et al. Reduction in All-Cause Mortality with Fluticasone Furoate/ Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2020;201(12):1508–1516. https://doi.org/10.1164/rccm.201911-2207OC.

13. Lipson D.A., Barnhart F., Brealey N., Brooks J., Criner G.J., Day N.C. et al. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. N Engl J Med. 2018;378(18):1671–1680. https://doi.org/10.1056/NEJMoa1713901.

14. Pascoe S.J., Lipson D.A., Locantore N., Barnacle H., Brealey N., Mohindra R. et al. A Phase III Randomised Controlled Trial of Single-Dose Triple Therapy in COPD: the IMPACT Protocol. Eur Respir J. 2016;48(2):320–330. https://doi.org/10.1183/13993003.02165-2015.

15. Lipson D.A., Barnacle H., Birk R., Brealey N., Locantore N., Lomas D.A. et al. FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2017;196(4):438–446. https://doi.org/10.1164/rccm.201703-0449OC.

16. López-Campos J.L., Quintana Gallego E., Carrasco Hernández L. Status of and Strategies for Improving Adherence to COPD Treatment. Int J Chron Obstruct Pulmon Dis. 2019;14:1503–1515. https://doi.org/10.2147/COPD.S170848.

17. Langham S., Lewis J., Pooley N., Embleton N., Langham J., Han M.K., Chalmers J.D. Single-Inhaler Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease: A Systematic Review. Respir Res. 2019;20(1):242. https://doi.org/10.1186/s12931-019-1213-9.

18. Ferguson G.T., Brown N., Compton C., Corbridge T.C., Dorais K., Fogarty C. et al. Once-Daily Single-Inhaler versus Twice-Daily Multiple-Inhaler Triple Therapy in Patients with COPD: Lung Function and Health Status Results from Two Replicate Randomized Controlled Trials. Respir Res. 2020;21(1):131. https://doi.org/10.1186/s12931-020-01360-w.

19. Avdeev S.N., Aisanov Z.R., Emelyanov A.V. First Triple Therapy in One Inhaler for COPD Patients: Treatment Approach (Scientific Data Overview). Pulmonologiya = Russian Pulmonology. 2020;30(6):813–821. (In Russ.) https://doi.org/10.18093/0869-0189-2020-30-6-813-821.

20. Pleasants R.A., Wang T., Gao J., Tang H., Donohue J.F. Inhaled Umeclidinium in COPD Patients: A Review and Meta-Analysis. Drugs. 2016;76(3):343–361. https://doi.org/10.1007/s40265-015-0532-5.

21. Hiller A.M., Piitulainen E., Jehpsson L., Tanash H. Decline in FEV1 and Hospitalized Exacerbations in Individuals with Severe Alpha-1 Antitrypsin Deficiency. Int J Chron Obstruct Pulmon Dis. 2019;14:1075–1083. https://doi.org/10.2147/COPD.S195847.

22. Zhudenkov K., Palmér R., Jauhiainen A., Helmlinger G., Stepanov O., Peskov K. et al. Longitudinal FEV1 and Exacerbation Risk in COPD: Quantifying the Association Using Joint Modelling. Int J Chron Obstruct Pulmon Dis. 2021;16:101–111. https://doi.org/10.2147/COPD.S284720.

23. Donaldson G.C., Law M., Kowlessar B., Singh R., Brill S.E., Allinson J.P., Wedzicha J.A. Impact of Prolonged Exacerbation Recovery in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2015;192(8):943–850. https://doi.org/10.1164/rccm.201412-2269OC.

24. Müllerová H., Hahn B., Simard E.P., Mu G., Hatipoğlu U. Exacerbations and Health Care Resource Use among Patients with COPD in Relation to Blood Eosinophil Counts. Int J Chron Obstruct Pulmon Dis. 2019;14:683–692. https://doi.org/10.2147/COPD.S194367.

25. Bolotova E.V., Dudnikova A.V. Chronic Kidney Disease in Patients with Chronic Obstructive Pulmonary Disease: A Role of Exacerbations. Pulmonologiya = Russian Pulmonology. 2016;26(5):578–583. (In Russ.) https://doi.org/10.18093/0869-0189-2016-26-5-578-583.

26. Bolotova E.V., Dudnikova A.V., Trembach V.V. The Potential for Correction of Depressive Disorders in Patients with Chronic Obstructive Pulmonary Disease. Al’manakh klinicheskoy meditsiny = Almanac of Clinical Medicine. 2020;48(5): 299–306. (In Russ.) https://doi.org/10.18786/2072-0505-2020-48-063.

27. Lutsey P.L., Chen N., Mirabelli M.C., Lakshminarayan K., Knopman D.S., Vossel K.A. et al. Impaired Lung Function, Lung Disease, and Risk of Incident Dementia. Am J Respir Crit Care Med. 2019;199(11):1385–1396. https://doi.org/10.1164/rccm.201807-1220OC.

28. Davison K.M., Lung Y., Lin S.L., Tong H., Kobayashi K.M., Fuller-Thomson E. Depression in Middle and Older Adulthood: the Role of Immigration, Nutrition, and Other Determinants of Health in the Canadian Longitudinal Study on Aging. BMC Psychiatry. 2019;19(1):329. https://doi.org/10.1186/s12888-019-2309-y.

29. Iyer A.S., Bhatt S.P., Garner J.J., Wells J.M., Trevor J.L., Patel N.M. et al. Depression Is Associated with Readmission for Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc. 2016;13(2):197–203. https://doi.org/10.1513/AnnalsATS.201507-439OC